Asarina And Emalex Carry The Torch For Tourette's
Alternatives To Antipsychotics Are Advancing
Executive Summary
The pipeline to treat the neurological disorder, which is characterized by uncontrolled rapid and repeated movements or sounds, is very thin but a couple of biotechs either side of the Atlantic are making progress.
You may also be interested in...
Finance Watch: Emalex Raises $250m To Fund Phase III Tourette’s Trial
Private Company Edition: The Paragon Biosciences-founded Emalex previously raised $35m when ecopipam was in Phase II. Also, Catalio Capital launches a “special situations” fund, Zenas raises $118m to develop a pipeline of autoimmune disease treatments and Lusaris emerges with $60m.
Andera Reflects On Revitalized Biotech Scene
After AstraZeneca’s acquisition of Amolyt made the Paris-based investment group a tidy profit, Andera spoke to Scrip about the rejuvenated investment market in Europe.
Tubulis Touts Transatlantic Plans As Cash Rolls In
The German biotech is benefitting from the heat in the antibody-drug conjugate space and has concluded an upsized series B2 financing for €128m.